InsiderClue
← All stocks

LENZ Therapeutics, Inc.

LENZ Net selling
CIK 0001815776 #4144 in the set updated 18 Sep 2026
Bought (12 mo)
$654.87K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$16.33M
$0.00 on a plan · $261.02K straight out of an exercise
Sold at will
$16.07M
12 of 14 sales
Net
−$15.67M
−$15.41M against sales at will

By person

6 insiders · 20 transactions
0.9×

Evert Schimmelpennink holds only 0.9 times base salary in stock. $662.37K of shares against $690.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Evert Schimmelpennink last reported holding, valued at $8.57, the price Common Stock was last bought or sold at on the open market here, on 27 Mar 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Versant Venture Capital VI, L.P. entity
10% owner
—
$16.07M (12)
−$16.07M
1,814,726
5.78%
$15.55M
−51.0%
Olsson Shawn
Chief Commercial Officer
—
$261.02K (2) scheduled
−$261.02K
4,733
0.0151%
$40.56K
—
Schimmelpennink Evert B.
President, CEO and Secretary
$251.41K (1)
—
+$251.41K
77,289
0.2460%
$662.37K
+71.8%
MCCOLLUM JAMES W
Director
$239.28K (1)
—
+$239.28K
10,500
0.0334%
$89.99K
—
Chevallard Daniel R.
Chief Financial Officer
$114.29K (3)
—
+$114.29K
12,886
0.0410%
$110.43K
+304.2%
George Jeffrey P.
Director
$49.89K (1)
—
+$49.89K
5,592
0.0178%
$47.92K
—

Individual transactions

2
Insider
Date
Role
Action
Shares
Price
Amount
Olsson Shawn
17 Nov 2025
Chief Commercial Officer
Sold after exercise
5,788
$26.37
$152.61K
Olsson Shawn
17 Nov 2025
Chief Commercial Officer
Sold after exercise
4,212
$25.74
$108.41K
Show all 20 transactions →

What was left out

Form 4 filings counted 19
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 2
Sales at will 12
Transactions with no price 0
Shares from compensation/vesting 10,000
History held since 28 Jun 2021